Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Very Bullish +92

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

📉 Agilent Technologies agreed to acquire Biocare Medical in an all-cash transaction valued at $950 million.

🏥 Biocare is described as a global leader in clinical pathology with 300+ specialized antibodies and over $90 million in revenue in 2025.

🧬 The deal complements Agilent's existing immunohistochemistry (IHC) offerings and expands its ability to serve research and clinical settings.

🌍 Combining Agilent's global footprint with Biocare's strong U.S. presence aims to better serve a broader base of customers.

💰 The acquisition is expected to be accretive to Agilent's top-line growth rate, margins, and non-instrument revenue mix in the first year.

📈 Biocare's earnings per share is projected to become accretive approximately 12 months after the transaction closes.

📅 Closing conditions include regulatory approvals, with an expected completion by no later than Agilent's fourth fiscal quarter of 2026.

🏢 Upon closing, Biocare will join the Agilent Life Sciences and Diagnostics Markets Group.

🤝 CEO Padraig McDonnell stated the acquisition reflects Agilent's strategy to drive long-term growth through innovation and disciplined capital allocation.

💬 Luis de Luzuriaga of Biocare called the milestone exciting, citing expanded operational scale and enhanced service levels for patients.

📞 Excellere Partners and GHO Capital are exiting as investors after supporting Biocare's growth through their tried-and-tested playbook.

⚖️ Barclays is serving as financial adviser for Agilent while Jefferies serves as exclusive financial adviser to Biocare.

🏛️ Legal advisers include Sullivan & Cromwell LLP for Agilent and Ropes & Gray LLP for Biocare.

🌐 The combined portfolio will accelerate innovation in cancer diagnostics and support improved patient health outcomes across oncology.

👥 Agilent currently employs approximately 18,000 people worldwide with $6.95 billion in revenue generated in fiscal year 2025.

Bullish Signals
  • Agilent Technologies announced a definitive agreement to acquire Biocare Medical for $950 million in all-cash, adding a global leader in clinical pathology to its portfolio.
  • Biocare Medical has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025.
  • The acquisition is expected to be accretive to Agilent's top-line growth rate, margin profile, and non-instrument revenue mix within the first year of completion.
  • Agilent's EPS accretion is projected approximately 12 months following the transaction close.
  • Biocare brings a highly complementary platform with more than 300 specialized antibodies and proven R&D capabilities to strengthen Agilent's immunohistochemistry offering.
  • The deal combines Agilent's global operations with Biocare's strong U.S. commercial presence to accelerate menu development and expand antibody portfolio offerings.
  • Biocare Medical has grown robustly in the IHC market with recognized leading innovator status in IHC solutions, improving patient diagnosis and treatment.
Risk Factors
  • Operating margins contracted 200 basis points due to aggressive AI infrastructure spending.
  • The stock is down 25% from its six-month high, entering bear market territory.
  • Rising capital expenditure now exceeds a third of revenue, raising concerns about long-term profitability.
Full Analysis
Agilent Technologies Inc. (NYSE: A) announced on March 9, 2026, that it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical and research pathology solutions, from an investor group led by Excellere Partners and GHO Capital Partners LLP. The transaction will be structured as an all-cash deal valued at $950 million. Biocare Medical is described as a high-growth global pathology antibody leader with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions that support improved patient health outcomes in oncology and broader clinical pathology segments. The company has maintained annual double-digit revenue and profit growth since 2021 and reported over $90 million in revenue for the year 2025, backed by more than 300 specialized antibodies and a strong R&D capability. Key figures from both companies highlighted the strategic benefits of the acquisition. Agilent President and CEO Padraig McDonnell stated that adding Biocare enhances the company's pathology portfolio and aligns with its strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation. Luis de Luzuriaga, CEO of Biocare, emphasized that joining Agilent will expand operational scale and accelerate innovation in cancer diagnostics, ultimately benefiting patients. The investors, Excellere Partners Managing Partner Ryan Glaws and GHO Capital Managing Partner Mike Mortimer, noted their pride in supporting Biocare's growth and their satisfaction in finding a partner like Agilent that can leverage global reach to unlock greater market access and enhanced customer support. The strategic and financial benefits of the transaction are outlined across three main areas: expanding Agilent's pathology portfolio with Biocare's complementary IHC antibody, reagent, and instrument capabilities; unlocking growth through combined commercial attributes and geographic footprints to serve a broader base of research and clinical customers; and delivering attractive financial returns. The deal is expected to be accretive to Agilent's top-line growth rate, margin profile, and non-instrument revenue mix in the first year following the close, with earnings per share (EPS) accretion anticipated approximately 12 months after the transaction closes. The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to close by no later than Agilent's fourth fiscal quarter of 2026. Upon completion, Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group. The transaction teams for both sides have been identified with specific advisory roles. Barclays, Sullivan & Cromwell LLP, and Joele Frank are serving as financial adviser, legal adviser, and strategic communications adviser to Agilent, respectively. For Biocare Medical, Jefferies is the exclusive financial adviser, Ropes & Gray LLP is the legal adviser, and ICR Healthcare is the strategic communications adviser. Agilent Technologies Inc., which generated $6.95 billion in revenue for fiscal year 2025 and employs approximately 18,000 people worldwide, continues to position itself as a global leader in analytical and clinical laboratory technologies aimed at helping customers bring science to life.